EGFR and cholangiocarcinoma: The incidence of KRAS mutation in cholangiocarcinoma is estimated to be 54–67% (Tada et al, 1990; Tannapfel et al, 2000), and therefore it may be important to examine the KRAS status when evaluating the activity of EGFR inhibitors in cholangiocarcinoma.